Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Gabapentin NDC 71610-757 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 300 mg - 71610 0753 94

Bottle Label 100 mg - 71610 0756 30

Bottle Label 400 mg - 71610 0757 53

Aphena Pharma Solutions - TN - Aphena

Equation - Equ

The given text appears to be a mathematical formula related to age, weight, and serum creatinine. It calculates the value by multiplying the difference between 140 and age (years) with weight (kg). Additionally, it calculates the value by multiplying 72 with serum creatinine (mg/dL). For female patients, an additional step of multiplying the result by 0.85 is mentioned.*

Fig 1 - FIG 1

Fig 2 - FIG 2

Fig 3 - FIG 3

Fig 4 - FIG 4

Structure - STRUCT

Table 1 - TAB 1

TABLE 1. Gabapentin Dosage Based on Renal Function This table provides dosing information for Gabapentin based on renal function. The dosage is adjusted based on the patient's creatinine clearance, which is a measure of kidney function. The table includes dosages for different levels of renal function, ranging from total dysfunction to normal function. The dosages are given in milligrams per day and are divided into different regimens, such as three times a day (TID), two times a day (BID), or a single daily dose (QD). For patients on hemodialysis, there is an additional supplemental dose recommended. The table also provides instructions for adjusting the dosage for patients with lower creatinine clearance.*

Table 2 - TAB 2

Table 3 - TAB 3

This is a list of adverse reactions reported in pooled placebo-controlled trials for the treatment of postherpetic neuralgia using Gabapentin. The reactions include asthenia (weakness), infection, accidental injury, digestive system issues such as diarrhea, dry mouth, constipation, nausea, and vomiting. There were also metabolic and nutritional disorders reported including peripheral edema, weight gain, and hyperglycemia. Nervous system reactions such as dizziness, somnolence (sleepiness), ataxia (loss of muscle control), abnormal thinking, and abnormal gait were reported. Additionally, there were respiratory system reactions like pharyngitis (sore throat), and special senses reactions including blurred vision, amblyopia (lazy eye), conjunctivitis (pink eye), and diplopia (double vision).*

Table 4 - TAB 4

Table 5 - TAB 5

Tab 6 - TAB 6

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.